论文部分内容阅读
目的:探讨高原地区前列地尔注射液对冠心病患者行冠状动脉造影术(primary coronary intervention,PCI)引起对比剂肾病的预防作用。方法:选择我院冠心病患者186例,分为两组:对照组93例(常规水化),观察组93例(前列地尔注射液+常规水化)。PCI前及术后24h、48h、72h分别测定尿素氮、血清肌酸酐及肌酐清除率,并观察造影住院总死亡率。结果:观察组和对照组的对比剂肾病发生率分别为3.2%(3/93)和11.8%(11/93),两组比较差异具有统计学意义(P<0.05)。结论:高原地区PCI患者使用前列地尔注射液可明显改善患者术后肾功能,降低对比剂肾病的发生率,减少肾损伤。
Objective: To investigate the preventive effect of alprostadil injection on contrast-induced nephropathy in patients with coronary heart disease undergoing primary coronary intervention (PCI). Methods: A total of 186 CHD patients were selected and divided into two groups: control group, 93 cases (conventional hydration), observation group, 93 cases (alprostadil injection + conventional hydration). Preoperative and postoperative 24h, 48h, 72h were measured urea nitrogen, serum creatinine and creatinine clearance rate, and to observe the overall hospital mortality rate of contrast. Results: The incidence of contrast-induced nephropathy in observation group and control group were 3.2% (3/93) and 11.8% (11/93), respectively. The differences between the two groups were statistically significant (P <0.05). Conclusion: Alprostadil injection can significantly improve postoperative renal function, reduce the incidence of contrast-induced nephropathy and reduce renal damage in PCI patients in high altitude.